AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00194844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self Caring
Description: Self Caring: Couples receive a mailed videotape and workbook at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
Study NCT00194844 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Caring
Description: Combined Caring: Couples receive one counseling session from a nurse interventionist at approximately one week after enrollment. Upon completion of the session the nurse will hand the couple a self-caring videotape and workbook. Couples will be mailed an additional videotape and workbook at approximately 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
Study NCT01647529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Treatment with topical ganciclovir ointment
Study NCT01523639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin/Placebo
Description: The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.~Duration of treatment: 24 weeks
Study NCT01523639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin/Placebo
Description: The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.~Duration of treatment: 24 weeks
Study NCT01585220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA filler
Description: The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.
Study NCT01585220 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA filler
Description: The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.
Study NCT01464229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iloperidone
Description: Iloperidone 1-8 mg for 4 weeks
Study NCT01464229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02896504 — intervention group
Intervention type: DRUG
Intervention: Exposure: Adjuvant chemotherapy treatment
Study NCT02896504 — intervention group
Intervention type: DRUG
Intervention: Exposure: Adjuvant hormonal therapy treatment
Study NCT03267940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: PEGPH20 will be administered as per the schedule specified in the respective arms.
Study NCT03267940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CIS
Description: CIS will be administered as per the schedule specified in the respective arms.
Study NCT03267940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIS
Description: CIS will be administered as per the schedule specified in the respective arms.
Study NCT03267940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GEM
Description: GEM will be administered as per the schedule specified in the respective arms.
Study NCT03267940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEM
Description: GEM will be administered as per the schedule specified in the respective arms.
Study NCT03267940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered as per the schedule specified in the respective arms.
Study NCT00622882 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: infectious disease specialist consultation
Description: Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
Study NCT02960347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-definition (HD) transcranial direct current stimulator, HD-tDCS with 4x1 HD adaptor
Description: Non-invasive focal neuromodulation
Study NCT02740972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NS-065/NCNP-01
Study NCT02740972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05078216 — intervention group
Intervention type: OTHER
Intervention: Physical exercise intervention
Description: 12-week supervised intervention, 90 minutes sessions twice per week All sessions had the same structure: 10 min of warm-up at 60-70% maximal heart rate (MHR), followed by 60-70 minutes of specific training and 10 minutes of stretching exercises. At least, 20% of the total session time was based on cardiovascular work over 70% of the maximum heart rate (MHR).~Fitness work in the first eight sessions was planned following 30 min of time on cardiovascular exercise 55 min on work out in low to moderate intensity. In the next eight sessions, the time spent on cardiovascular work was slightly increased to 35 min, with 50 min focused on work out, combining moderate to high-intensity sessions. The last eight sessions presented the same structure as the first ones but combining moderate to high intensity.
Study NCT00327054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella sativa seed
Study NCT03211650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic Acid + platelet-rich plasma
Description: Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
Study NCT04171843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.
Study NCT03211650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyaluronic acid
Description: Intra-articular injections of hyaluronic acid
Study NCT03211650 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: platelet-rich plasma
Description: Intra-articular injections of platelet-rich plasma
Study NCT01910805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle and Risk Assessment class
Description: Classes will be conducted by a CITI-certified Boston Public Health Commission nutritionist, who is a consultant on this project and has previously worked within the Boston African-American community to increase diabetes awareness and reduce diabetes risk. These classes will be held at a local community center to provide maximal accessibility to the women.~The intervention group will attend classes mentioned at the aforementioned centers. Each class will take 2-hours and be conducted by a CITI-certified registered nutritionist with extensive knowledge of working in the African-American community. Both classes will include a cooking demonstration. In addition, the class will include a tour of a local supermarket to aid women in identifying healthy food choices.
Study NCT01605253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eszopiclone
Description: Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
Study NCT01605253 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
Study NCT01210989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phyllanthus urinaria
Description: Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.
Study NCT01210989 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.
Study NCT04622189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Action observation training
Description: Integration of four main tools:~* PATIENT INTERFACE, which has been implemented to present stimuli with a user friendly interface, with personalized menu and with the possibility to manage the training program; user personal page containing user information and history of activities with daily performance are stored too.~* MOCAP during action imitation will be recorded using MindMotion infrared camera to capture the trunk movement while an electromagnetic system (Trackstar from NDI) will be used to record fingers fine movements.~* EEG data will be collected during video observation using an Enobio wireless system integrated with the platform.
Study NCT04561752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5 is the study drug.
Study NCT02993653 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High-dose Intensity-modulated radiotherapy
Description: Pelvic High-dose Intensity-modulated radiotherapy with stereotactic radiotherapy or intracavitary radiotherapy
Study NCT01367353 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery or debulking surgery
Description: surgery or debulking surgery
Study NCT04298723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous closure of the LAA (Watchman / Watchman FLX)
Description: LAA closure procedure will be done by experienced operators according to the local SOP. LAA closure will be performed under fluoroscopic and TEE guidance within conscious sedation or general anesthesia. Antibiotic single-shot prophylaxis should be administered peri-procedurally (i.e., cefazolin 2 g). The specific anatomy of the LAA is evaluated and an appropriately sized CE-marked device (WatchmanTM or Watchman FLXTM) is deployed. LAA angiography and TEE imaging is performed to identify optimal positioning of the device and to exclude a relevant leak. Following device deployment, patients will receive a therapy according to the manufacturers IFU, currently Aspirin and clopidogrel for 3 months followed by single Aspirin up to 12 months. Alternatively, 3 months of NOAC followed by Aspirin monotherapy up to 12 months are possible.
Study NCT02679742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-hydroxymethylbutyrate
Description: β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
Study NCT02679742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
Study NCT04427553 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Peripheral Nerve Stimulation
Description: Participants assigned to this group will received two sessions (once per week) of ultrasound guided Percutaneous Peripheral Nerve Stimulation targeting the femoral nerve.
Study NCT04427553 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: No intervention
Study NCT00460551 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zalutumumab
Description: 8 mg/kg
Study NCT00460551 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Description: Combination of cisplatin and docetaxel administered as two cycles given every three weeks
Study NCT00460551 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 64 Gy in 32 fractions over 6.5 weeks
Study NCT01840605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate
Description: Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
Study NCT01840605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketotifen fumarate
Description: Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
Study NCT02873273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day
Study NCT02279862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Study NCT03228381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BOSS Device
Description: The BOSS will be comprised of a flexible, medical grade silicone handle and interchangeable inflatable medical grade silicone chambers. The inflatable chambers will vary in geometry and will have silicone tubing attached to them to allow inflation and deflation of the chamber while in the pericardial space. During open chest cardiac surgery, a small incision will be made in the pericardium to allow for insertion of the BOSS device into the pericardial space. Once inserted, the BOSS device will be positioned in different locations around the outside of the heart and anatomical and geometric changes will be observed echocardiographically. Use of the BOSS device is expected to lengthen the procedure by an average of 15 minutes, and in rare instances may be extended beyond 15 minutes as deemed appropriate by the investigator. The BOSS will be removed prior to continuing with the planned surgery.
Study NCT03298321 — intervention group
Intervention type: OTHER
Intervention: Effect of Vidaza treatment
Description: The goal of this study is to evaluate the effects of azacytidine on arrhythmia and left atrium fibrosis.
Study NCT02798263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Description: Compare the standard treatment of pain, by kinesiotherapy versus acupuncture and Stiper.Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
Study NCT02798263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 30 minutes of classical acupuncture using predefined points.
Study NCT02798263 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stiper
Description: They will be used the same acupuncture points of the group II, but using the needles in place Stiper.
Study NCT04171843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirogacestat
Description: Allogeneic anti-BCMA CAR T-cell
Study NCT01206725 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: 1. Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.~2. Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min.
Study NCT01094119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: heated blanket
Description: heated blanket
Study NCT01130974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bausch & Lomb contact lens
Description: Bausch \& Lomb daily disposable cosmetic tint contact lens
Study NCT01130974 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Marketed daily disposable contact lens
Description: Marketed daily disposable cosmetic tint contact lens
Study NCT02929745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Four 4-5 mm punch biopsies of the skin
Study NCT02929745 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Blood will be drawn to test for HLA-cw6 status
Study NCT01143103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough assist (Philips,respironics)
Study NCT01143103 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual respiratory therapy
Study NCT03782142 — intervention group
Intervention type: DRUG
Intervention: Tenofovir
Description: TAF (tenofovir alafenamide) or TDF(tenofovir disoproxil fumarate)
Study NCT03782142 — intervention group
Intervention type: DRUG
Intervention: Rilpivirine
Description: NNRTI
Study NCT03782142 — intervention group
Intervention type: DRUG
Intervention: Prezcobix
Description: PI
Study NCT03782142 — intervention group
Intervention type: DRUG
Intervention: Dolutegravir
Description: II
Study NCT00768391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-3G3
Description: Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
Study NCT00569816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: 1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
Study NCT00569816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
Study NCT01615653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS
Description: EUS Guided Therapy
Study NCT00651157 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: wild-type reovirus
Description: Given IV: Administered at a dose of 3 x 10\^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.
Study NCT01721603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: 150 mg capsule by mouth twice daily
Study NCT01721603 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gamma Knife Radiosurgery
Description: This will be delivered using Gamma Knife technology. Patients will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
Study NCT01721603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: 2 mg by mouth once daily from beginning at Cycle 3 Day 1, until progression of disease, withdrawal of consent, or the development of intolerable treatment associated toxicity.
Study NCT00916630 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: pemetrexed
Description: Given intravenously over a 10 to 20 minute period once every 14 days.
Study NCT04379648 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: self-assessment and hetero-assessment
Description: Self assessment for the passing of the following rating scales CTQ-SF36-ITQ-PCL5-DES Hetero-assessment for the pasing of the following rating scales DDIS FR and medical interview
Study NCT04047654 — intervention group
Intervention type: DRUG
Intervention: Non vitamin K oral anticoagulants
Description: Non vitamin K oral anticoagulants are apixaban, dabigatran, rivaroxaban, and edoxaban
Study NCT02472080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine -oxaliplatine combination
Description: gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
Study NCT00248846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
Study NCT03620019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: A dose of 120 mg will be administered as a subcutaneous (s.c.) injection every 4 weeks in the upper arm, upper thigh, or abdomen. Another loading dose of 120 mg s.c. denosumab will be administered on day 8. On days when denosumab is administered on the same day as pembrolizumab, the s.c. injection should be given after the infusion of pembrolizumab is completed.
Study NCT03620019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as standard of care following the institutional guidelines.The recommended dose of pembrolizumab is 200 mg administered as an IV infusion over approximately 30 minutes (range: 25 - 40 minutes) every 3 weeks until disease progression or unacceptable toxicity.
Study NCT03620019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given every four weeks at a dose of 480 mg to be administered as an IV infusion per institutional guidelines.
Study NCT02884765 — intervention group
Intervention type: PROCEDURE
Intervention: Non-surgical
Description: Non-surgical treatment in both condylar fractures